The FDA has approved elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with estrogen receptor–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy.
A version of this article was originally published on OncLive. This version has been lightly edited.
The FDA Friday approved elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with estrogen receptor–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy.
The FDA also approved the Guardant360 Dx assay as a companion diagnostic device to identify patients who are eligible to receive elacestrant.
The regulatory decision was based on data from the randomized, open-label, active-controlled, multicenter phase 3 EMERALD trial (NCT03778931), in which the oral selective estrogen degrader (SERD; n = 115) reduced the risk of disease progression or death by 45% compared with fulvestrant (Faslodex) or an aromatase inhibitor (n = 113) in this population. The median progression-free survival with elacestrant was 3.8 months (95% CI, 2.2-7.3) vs 1.9 months (95% CI, 1.9-2.1) with the control (HR, 0.55; 95% CI, 0.39-0.77; P = .0005).
EMERALD enrolled patients with ER-positive/HER2-negative breast cancer who had progressed on 1 to 2 lines of endocrine therapy, including 1 line that contained a CDK4/6 inhibitor. Patients were able to have received up to 1 previous line of chemotherapy in either the advanced or metastatic setting.
Enrolled patients were randomly assigned in a 1:1 fashion to receive 345 mg of oral elacestrant per day (n = 239) or investigator’s choice of endocrine therapy, which could have been fulvestrant (Faslodex; n = 166) or an aromatase inhibitor such as anastrozole, letrozole, or exemestane (n = 73). Patients received treatment until progressive disease or intolerable toxicity.
Patients were stratified based on ESR1 mutational status (yes vs no), previous fulvestrant exposure (yes vs no), and the presence of visceral metastases (yes vs no).
ESR1 status was determined by blood circulating tumor DNA (ctDNA) using the Guardant360 CDx assay and was limited to ESR1 missense mutations in the ligand binding domain.
PFS by blinded imaging review committee assessment served as the major efficacy outcome of the trial. Overall survival was an additional efficacy outcome.
An exploratory analysis of PFS for patients without ESR1 mutations (n = 250) showed a HR of 0.86 (95% CI, 0.63-1.19), which is indicative that the improvement observed in the intention-to-treat population was primary attributed to the data observed in the ESR1-mutated population.
Among the patients with ESR1 mutations, the median age was 63 years (range, 28-89) and all were female. Most (72%) of patients were White, 5.7% were were Asian, 3.5% Black, and 0.4% were other; this information was not known or reported in 18.4% of patients. Fifty-seven percent of patients had an ECOG performance status of 0 at baseline and 43% had a status of 1. Most patients (71%) had visceral disease (71%).
Additionally, 62% of patients had received 1 line of endocrine therapy and 39% had received 2 lines in the advanced or metastatic setting. All had previous treatment with a CDK4/6 inhibitor, 24% had prior fulvestrant, and 25% had prior chemotherapy.
Regarding safety, the most common adverse effects observed in at least 10% of patients treated with elacestrant, including laboratory abnormalities, were musculoskeletal pain, nausea, increased cholesterol, increased aspartate aminotransferase, increased triglycerides, fatigue, decreased hemoglobin, vomiting, increased alanine transaminase, decreased sodium, increased creatinine, decreased appetite, diarrhea, headache, constipation, abdominal pain, hot flush, and dyspepsia.
Ocular MG Should Be Considered in Patients With Ptosis, Diplopia, Says Study
With most previous studies on ocular myasthenia gravis stemming from investigations the neurology field, the present investigators came to their conclusion via neuro-ophthalmic analysis.
Read More
Examining Telehealth Uptake to Increase Equitable Care Access
To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
Racial Disparities Among US Neighborhoods May Have Implications for Health Outcomes
Large geographical data may offer insight on race and ethnic health inequities across the United States.
Read More
High-Deductible Health Plans and Their Potential Impact on the US Drug Epidemic
On this episode of Managed Care Cast, we speak with Matthew D. Eisenberg, PhD, lead author of a study published in the October issue of The American Journal of Managed Care® that investigated the use of high-deductible health plans and their impact on substance use disorder care and spending.
Listen
FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
The FDA has approved pirtobrutinib (Jaypirca) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma following at least 2 lines of systemic therapy, including a previous Bruton tyrosine kinase (BTK) inhibitor.
Read More
Female Adolescents With T1D Have Lower Quality of Life Than Male Children
A systematic review evaluating sex differences in children with type 1 diabetes (T1D) found that female children had higher rates of comorbidities, higher body mass index, required higher insulin doses, and had a lower quality of life compared with male children.
Read More
2 Clarke Drive
Cranbury, NJ 08512
609-716-7777